Knopp Biosciences Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

Knopp Biosciences General Information

Description

Developer of immunological and neurological drugs designed to change the course of human health. The company's drugs are dexpramipexole, which are small molecules of immunological therapeutics based on its pre-clinical and clinical activity in modulating white blood cells, enabling medical professionals to address unmet needs and thereby improve their patients' lives.

Contact Information

Formerly Known As
Knopp Neurosciences
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 2403 Sidney Street
  • Suite 206
  • Pittsburgh, PA 15203
  • United States
+1 (412)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 2403 Sidney Street
  • Suite 206
  • Pittsburgh, PA 15203
  • United States
+1 (412)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Knopp Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Merger/Acquisition 01-Apr-2022 Completed Clinical Trials - Phase 2
13. Later Stage VC Completed Clinical Trials - Phase 2
12. Later Stage VC (Series C) 11-Nov-2020 Completed Clinical Trials - Phase 2
11. Grant 22-Jul-2020 Completed Clinical Trials - General
10. Debt - PPP 14-Apr-2020 Completed Clinical Trials - General
9. Grant 01-Jan-2019 Completed Clinical Trials - General
8. Secondary Transaction - Private Completed Clinical Trials - General
7. Later Stage VC 01-Jan-2014 Completed Clinical Trials - General
6. Later Stage VC 01-Nov-2012 $30M $119M Completed Clinical Trials - General
5. Later Stage VC 18-Aug-2010 $60M $88.6M Completed Clinical Trials - General
To view Knopp Biosciences’s complete valuation and funding history, request access »

Knopp Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immunological and neurological drugs designed to change the course of human health. The company's drugs are
Drug Discovery
Pittsburgh, PA
6 As of 2024

San Francisco, CA
 

Broomfield, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Knopp Biosciences Competitors (23)

One of Knopp Biosciences’s 23 competitors is Herophilus, a Formerly VC-backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Herophilus Formerly VC-backed San Francisco, CA
Cerecin Venture Capital-Backed Broomfield, CO
CervoMed Formerly VC-backed Boston, MA
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
T3D Therapeutics Venture Capital-Backed Durham, NC
You’re viewing 5 of 23 competitors. Get the full list »

Knopp Biosciences Patents

Knopp Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250171429-A1 Pyrazolyl compounds as kv7 channel activators Pending 23-Feb-2022
US-20250230152-A1 Pyrazolyl compounds as kv7 channel activators Active 23-Feb-2022
US-20260200908-A1 Pyrazolyl compounds as kv7 channel activators Pending 23-Feb-2022
WO-2022031956-A1 Use of dexpramipexole for the treatment of moderate to severe asthma Inactive 05-Aug-2020
EP-4031548-A1 Methods of use for kv7 channel activators Inactive 17-Sep-2019 A61K31/4184
To view Knopp Biosciences’s complete patent history, request access »

Knopp Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Knopp Biosciences Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Biogen Corporation Minority
Innovation Works Venture Capital Minority
Kramer Capital Partners Investment Bank Minority
LaunchCyte Venture Capital Minority
Angel (individual) Minority
You’re viewing 5 of 12 investors. Get the full list »

Knopp Biosciences FAQs

  • When was Knopp Biosciences founded?

    Knopp Biosciences was founded in 2004.

  • Where is Knopp Biosciences headquartered?

    Knopp Biosciences is headquartered in Pittsburgh, PA.

  • What is the size of Knopp Biosciences?

    Knopp Biosciences has 6 total employees.

  • What industry is Knopp Biosciences in?

    Knopp Biosciences’s primary industry is Drug Discovery.

  • Is Knopp Biosciences a private or public company?

    Knopp Biosciences is a Private company.

  • What is Knopp Biosciences’s current revenue?

    The current revenue for Knopp Biosciences is .

  • How much funding has Knopp Biosciences raised over time?

    Knopp Biosciences has raised $202M.

  • Who are Knopp Biosciences’s investors?

    Biogen, Innovation Works, Kramer Capital Partners, LaunchCyte, and are 5 of 12 investors who have invested in Knopp Biosciences.

  • Who are Knopp Biosciences’s competitors?

    Herophilus, Cerecin, CervoMed, Neurona Therapeutics, and T3D Therapeutics are some of the 23 competitors of Knopp Biosciences.

  • When was Knopp Biosciences acquired?

    Knopp Biosciences was acquired on 01-Apr-2022.

  • Who acquired Knopp Biosciences?

    Knopp Biosciences was acquired by Biohaven.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process